FDA: Prilosec Reduces Plavix’s Effectiveness

The FDA is requiring a labeling change to Sanofi-Aventis and Bristol-Myers Squibb’s blockbuster anti-blood-clotting drug Plavix to indicate that it should not be used with AstraZeneca’s stomach-acid treatment Prilosec and some other acid-reducing drugs. An FDA-requested study done by Sanofi found that Prilosec (omeprazole) reduced the anti-blood-clotting effect of Plavix (clopidogrel) by almost half when the two medicines were given to the same patient, the FDA says in a public health advisory Tuesday.
Drug Industry Daily